Tafluprost is well tolerated in OHT eyes

Article

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT).

Preservative-free tafluprost is well tolerated in eyes with glaucoma or ovular hypertension (OHT), reveals an investigation in the British Journal of Ophthalmology.

Dr Elena Milla and her team, Glaucoma and Genetics Unit, Institut Comtal d'Oftalmologia, Barcelona, Spain, conducted a prospective non-interventional, multicentre, observational study on 134 patients. Follow-ups were completed at baseline and one and three months post-treatment.

Five ocular surface symptoms were evaluated as absent, mild, moderate and severe. Tear break-up time, keratitis, conjunctival hyperaemia, blepharitis, Schirmer test and tear meniscus were all assessed in each patient.

A significant improvement in all symptoms was seen in 53% of patients with OHT. This included stinging/burning/irritation, itching, foreign body sensation, tearing and dryness sensation three months after treatment.

All signs except the Schirmer test results improved in the OHT patients. In the glaucomatous eyes the keratitis, hyperaemia and tear meniscus improved at one and three months post-treatment.

Preservative-free tafluprost is a well-tolerated hypotensive agent that can be used to treat naïve eyes and eyes with ocular surface problems.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.